Faeth Therapeutics reported net income of -$16.05M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 30.59M | 30.61M | 30.68M | 30.72M | 30.72M | 30.76M | 30.97M | 26.58M | 25.00M | 25.03M | 25.07M | 25.12M | 25.15M | 25.18M | 25.21M | 1.26M | 1.26M | 1.26M | 1.34M | 5.64M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | ||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 3.87M | 3.46M | 5.03M | 4.32M | 4.75M | 5.70M | 5.80M | 5.39M | 3.92M | 3.65M | 3.81M | 3.20M | 3.19M | 2.83M | 3.55M | 2.67M | 2.31M | 2.79M | 19.71M | 9.21M | ||||||
| Other Operating ExpensesOther Opex | 0.02M | 7.46M | 6.39M | 9.19M | 7.34M | -0.10M | -0.19M | -0.01M | 4.92M | 5.44M | 0.02M | -0.04M | -0.00M | 2.17M | 150.91M | 9.18M | ||||||||||
| Operating ExpensesOpex | 10.32M | 9.41M | 12.49M | 10.71M | 13.94M | 13.05M | 11.01M | 10.18M | 7.74M | 8.14M | 8.73M | 7.79M | 7.82M | 8.27M | 7.27M | 5.21M | 4.85M | 4.96M | 170.63M | 18.39M | ||||||
| Operating IncomeOp. Inc | -10.32M | -9.41M | -12.49M | -10.71M | -13.94M | -13.05M | -11.01M | -10.18M | -7.74M | -8.14M | -8.73M | -7.79M | -7.82M | -8.27M | -7.27M | -5.21M | -4.85M | -4.96M | -170.63M | -18.39M | ||||||
| EBIT | -10.32M | -9.41M | -12.49M | -10.71M | -13.94M | -13.05M | -11.01M | -10.18M | -7.74M | -8.14M | -8.73M | -7.79M | -7.82M | -8.27M | -7.27M | -5.21M | -4.85M | -4.96M | -170.63M | -18.39M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.21M | 0.31M | 0.24M | 0.17M | 0.01M | -0.21M | 0.04M | 0.04M | 0.03M | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | 0.00M | ||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.28M | 0.33M | -0.57M | -0.31M | 0.52M | 0.61M | 0.18M | 0.27M | 0.88M | 0.83M | 0.07M | 0.04M | 0.59M | 0.52M | 0.01M | 0.31M | 0.29M | 0.22M | -0.03M | 2.26M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.57M | 0.01M | 0.02M | 0.00M | 0.01M | 0.07M | -0.23M | -0.07M | -0.00M | -0.00M | 0.02M | -0.04M | -0.00M | -0.00M | 0.12M | |||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -10.25M | -9.38M | -13.30M | -11.20M | -13.44M | -12.23M | -10.87M | -9.94M | -6.89M | -7.35M | -8.69M | -7.77M | -7.25M | -7.77M | -7.28M | -4.91M | -4.57M | -4.74M | -170.65M | -16.13M | ||||||
| Profit After TaxPAT | -9.69M | -9.63M | -12.40M | -10.54M | -13.42M | -12.03M | -10.18M | -9.39M | -7.12M | -7.41M | -7.99M | -7.14M | -7.25M | -7.77M | -6.86M | -4.94M | -4.57M | -4.70M | -170.24M | -16.05M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -10.25M | -9.38M | -13.30M | -11.20M | -13.44M | -12.23M | -10.87M | -9.94M | -6.89M | -7.35M | -8.69M | -7.77M | -7.25M | -7.77M | -7.28M | -4.91M | -4.57M | -4.74M | -170.65M | -16.13M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -10.25M | -9.38M | -13.30M | -11.20M | -13.44M | -12.23M | -10.87M | -9.94M | -6.89M | -7.35M | -8.69M | -7.77M | -7.25M | -7.77M | -7.28M | -4.91M | -4.57M | -4.74M | -170.65M | -16.13M | ||||||
| Income towards Parent CompanyParent Net Inc | -10.25M | -9.38M | -13.30M | -11.20M | -13.44M | -12.23M | -10.87M | -9.94M | -6.89M | -7.35M | -8.69M | -7.77M | -7.25M | -7.77M | -7.28M | -4.91M | -4.57M | -4.74M | -170.65M | -16.13M | ||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -9.69M | -9.37M | -12.40M | -10.54M | -13.42M | -12.23M | -10.18M | -9.39M | -7.12M | -7.41M | -7.99M | -7.14M | -7.25M | -7.77M | -6.86M | -4.94M | -4.57M | -4.72M | -170.24M | -16.01M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.32 | -0.34 | -0.40 | -0.34 | -0.44 | -0.40 | -0.33 | -0.31 | -0.28 | -0.27 | -0.32 | -0.28 | -0.29 | -0.31 | -0.27 | -3.91 | -3.62 | -3.74 | -131.45 | -2.84 | ||||||
| EPS (Diluted) | -0.32 | -0.34 | -0.40 | -0.34 | -0.44 | -0.40 | -0.33 | -0.31 | -0.28 | -0.27 | -0.32 | -0.28 | -0.29 | -0.31 | -0.27 | -3.91 | -3.62 | -3.74 | -131.45 | -2.84 | ||||||
| Shares Outstanding | 30.59M | 27.71M | 30.65M | 30.70M | 30.72M | 30.70M | 30.87M | 30.51M | 25.51M | 27.95M | 25.05M | 25.10M | 25.15M | 25.12M | 25.19M | 1.26M | 1.26M | 1.26M | 1.30M | 5.64M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 30.59M | 27.71M | 30.65M | 30.70M | 30.72M | 30.70M | 30.87M | 30.51M | 25.51M | 27.95M | 25.05M | 25.10M | 25.15M | 25.12M | 25.19M | 1.26M | 1.26M | 1.26M | 1.30M | 5.64M | ||||||
| EBITDA | -10.32M | -9.41M | -12.49M | -10.71M | -13.94M | -13.05M | -11.01M | -10.18M | -7.74M | -8.14M | -8.73M | -7.79M | -7.82M | -8.27M | -7.27M | -5.21M | -4.85M | -4.96M | -170.63M | -18.39M | ||||||
| Interest ExpensesInt Expense | 0.21M | 0.31M | 0.24M | 0.17M | 0.01M | -0.21M | 0.04M | 0.04M | 0.03M | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M | 0.00M |